Find A PhysicianHome  |  Library  |  myDownstate  |  Newsroom  |  A-Z Guide  |  E-mail  |  Contact Us  |  Directions
curve gif

Full Time Faculty

« Previous | Next »


No photo of Michael Szarek

Michael Szarek, PhD, MS

Interim Associate Dean for Research Administration

Chair and Research Associate Professor

Department of Epidemiology and Biostatistics

Tel: (718) 804-7834 • Fax: (718) 270-2533

e-mail: Michael.Szarek@downstate.edu

  • About
  • Publications
Academic Qualifications:
  • PhD: New York University
  • MS: Harvard University School of Public Health
Background and Expertise:

Michael Szarek, PhD, is a Research Associate Professor and Chair of the Department of Epidemiology and Biostatistics. Dr. Szarek also currently serves as Interim Associate Dean for Research Administration. He received his MS degree in biostatistics from Harvard School of Public Health and his PhD in biostatistics from New York University.

Michael has been involved in the design, conduct, and analysis of several late-stage cardiovascular and oncology clinical trials. These activities have included membership on Steering Committees and Data Safety Monitoring Committees and leading interactions with worldwide regulatory agencies. Immediately prior to joining SUNY Downstate, Michael was Senior Director, Regulatory Affairs at ImClone Systems, where he was responsible for the worldwide regulatory strategies of development-stage treatments for cancer. His statistical research interests include missing data issues in illness-death models and surrogate endpoints in cardiovascular and oncology clinical trials. Michael also has interests in worldwide regulatory policies and strategies for the design and conduct of clinical trials.

Selected Publications:
  • Panichpisal, K., Szarek, M., Sareen, A. Dabigatran for stroke prevention in patients with atrial fibrillation and previous stroke or transient ischemic attack: does dose matter? Future Neurology, 2011; 6: 155-158.
  • Frydman, H., Szarek, M. “Illness-death” model for the vertical transmission of HIV-1. Statistics in Medicine 2010; 29: 2045-2054.
  • Frydman, H., Szarek, M. Nonparametric estimation in a Markov “illness-death” process from interval censored observations with missing intermediate event status. Biometrics, 2009; 65: 143-151.
  • Kastelein, J. P. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., Grundy, S. M. Lipids, apolipoproteins and their ratios in relation to cardiovascular events on statin treatment: Pooled analyses of the TNT and IDEAL trials. Circulation, 2008; 117: 3002-3009.
  • Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., Fruchart, J. C. HDL cholesterol and cardiovascular events in patients with very low LDL cholesterol. New England Journal of Medicine, 2007; 357: 1301-1310.
  • Amarenco, P., Bogousslavsky, J., Callahan, A., Goldstein, L. B., Hennerici, M., Rudolph, A. E., Sillesen, H., Simunovic, L., Szarek, M., Welch, K. M. A., Zivin, J. A. High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 2006; 355: 549-559.
Selected Presentations:
  • Szarek, M., Katz, T. Establishing biomarkers that are predictive of efficacy in retrospective analyses. Presented at the 2009 Joint Statistical Meetings, Washington, D.C. (Biopharmaceutical section roundtable discussion).
  • Frydman, H., Szarek, M. “Illness-death” model for the vertical transmission of HIV-1. Presented at the 2009 Joint Statistical Meetings, Washington, D.C.
  • Tikkanen, M. J., Szarek, M., Cater, N. B., Holme, I., Faergeman, O., Kastelein, J. P. P., Larsen, M. L., Olsson, A. G., Pedersen, T. R. Intensive statin therapy reduces risk of cardiovascular disease beyond occurrence of first event: Analysis of the IDEAL trial. Presented at the 2007 American Heart Association Scientific Sessions, Orlando, FL.
  • Sillesen, H., Callahan, A., Zivin, J. A., Amarenco, P., Goldstein, L. B., Hennerici, M., Rudolph, A. E., Simunovic, L., Szarek, M., Welch, K. M. A., Increased risk of coronary heart disease after recurrent cerebrovascular events – findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Presented at the 2007 American College of Cardiology Scientific Sessions, New Orleans, LA.
  • Amarenco, P., Rudolph, A. E., Szarek, M., Welch, K. M. A. Stroke and TIA as CHD risk equivalents: Findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Presented at the 2006 American Heart Association Scientific Sessions, Chicago, IL.